Source: Zacks

MicroVention: Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Read full article »
Est. Annual Revenue
$100-500M
Est. Employees
1.0-5.0K
Carsten Schroeder's photo - President & CEO of MicroVention

President & CEO

Carsten Schroeder

CEO Approval Rating

89/100

Read more